Belvedere Trading’s Lipocine LPCN Stock Holding History

Belvedere Trading’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-265	Closed	-$1.79K	–	1234
2022 Q4	$1.79K	Buy	+265	New	+$1.93K	﹤0.01%	1052

Other funds holding LPCN

EWA

EP Wealth Advisors Torrance, California $20.3B AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Belvedere Trading's LPCN Position: Q1 2023 in Review

Belvedere Trading sold out of Lipocine (LPCN) in Q1 2023, closing a stake of 247 shares — an estimated $1.67K sold.

Belvedere Trading first reported a position in LPCN in Q4 2022 and held it in 1 quarter. The position peaked at $1.67K in Q4 2022. 45 funds tracked by Wall St. Rank hold LPCN as of Q1 2023.

Belvedere Trading reported no remaining Lipocine position as of Q1 2023 after selling out during the quarter.
Belvedere Trading sold 247 Lipocine shares in Q1 2023, an estimated $1.67K.
Belvedere Trading first reported a position in Lipocine in Q4 2022 and held it in 1 quarter.
Belvedere Trading's Lipocine position peaked at $1.67K in Q4 2022.
45 funds tracked by Wall St. Rank held Lipocine as of Q1 2023.

Based on Belvedere Trading's 13F filing for Q1 2023, filed 15 May 2023.